BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.

BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.

In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses the TOP trial of osimertinib plus chemotherapy in high-risk patients with non-small cell ...

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...

“Setidegrasib is the first drug in this KRAS degrader class targeting KRAS G12D in solid tumors,” lead investigator Wungki ...

China NMPA approves Dizal's sunvozertinib to treat locally advanced or metastatic NSCLC with EGFR Exon20ins mutations: Shanghai Thursday, August 24, 2023, 18:00 Hrs [IST] Dizal, a ...

Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...

Nuvalent submits NDA to US FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC: Cambridge, Massachusetts Wednesday, April 8, 2026, 13:00 Hrs [IST] Nuvalent, Inc., a ...

Leah Phillips was diagnosed with Stage 4 lung cancer at 43. She never smoked, but a genetic mutation allowed the cancer to ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be ...

New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will present new research at the American Association for Cancer Research (AACR) Annual Meeting, highlighting ...